Beyond Tax Benefits: Portfolio Opportunities In A Pfizer-Allergan Deal
This article was originally published in Scrip
Executive Summary
Pfizer Inc. and Allergan plc continue to be in closed-door discussions regarding a potential merger that could significantly cut Pfizer's tax rate due to Allergan's Irish corporate base, but Allergan also has several commercial products and research-stage assets that could fill gaps in Pfizer's portfolio.
You may also be interested in...
Allergan’s Namesake Acquisition Looks Well-Timed As Established Brands Falter
Allergan’s net product revenue in the third quarter fell slightly below analyst consensus, but revenue from the company’s 2015 purchase of Botox, Restasis and other products softened declines for established products Namenda and Asacol.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.